Studies whose primary subject is both MDMA and PTSD, with an evidence synthesis read across the most-cited and most recent of them.
Synthesized from 23 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, PTSD, post-traumatic stress disorder, then ranked by relevance.
Across multiple randomized trials and meta-analyses, MDMA-assisted therapy consistently reduces PTSD symptoms more than placebo or low-dose MDMA combined with therapy, with moderate-to-large effect sizes (roughly d = 0.7-0.9 on clinician-rated scales) and higher rates of losing the PTSD diagnosis. Benefits appear durable in long-term follow-up, though relapse occurs in a minority. The main caveats are small samples in early trials, difficulty blinding participants to MDMA's effects, non-standardized therapy protocols, a common sponsor across trials, and unresolved ethical and safety questions.
Direction is which way each study's own result points, not our rating of the study.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. 2021 | RCT | 90 | Supports | MDMA-assisted therapy produced significantly greater reductions in PTSD symptoms (d = 0.91) and functional impairment (d = 0.43) than placebo with therapy, with no serious adverse events. |
| The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. 2010 | randomized controlled pilot study | Supports | MDMA-assisted psychotherapy reduced PTSD symptoms more than placebo therapy in people with chronic, treatment-resistant PTSD. | |
| 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. 2018 | randomized, double-blind, dose-response phase 2 trial | Supports | The active dose of MDMA-assisted psychotherapy led to significant and lasting reductions in PTSD symptoms compared to a lower dose. | |
| A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD) 2012 | RCT | 12 | Mixed | MDMA-assisted psychotherapy was safely administered and produced statistically significant self-reported improvement (PDS, p = 0.014), but clinician-rated CAPS reductions were not statistically significant (p = 0.066); CAPS scores improved further at 1-year follow-up. |
| MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. 2023 | RCT | 104 | Supports | MDMA-assisted therapy reduced PTSD symptoms (d = 0.7) and functional impairment (d = 0.4) more than placebo with therapy; no deaths or serious treatment-emergent adverse events occurred. |
| Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. 2013 | long-term follow-up of a completed trial | 19 | Supports | Gains in symptom relief were maintained over an average of 45.4 months with no statistical difference between end-of-study and follow-up CAPS scores, though two of 16 completers relapsed. |
| Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. 2016 | review | Supports | MDMA is showing encouraging results as a treatment for refractory PTSD when used as an adjunct to psychotherapy, though further research is needed. | |
| 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. 2018 | RCT | 28 | Supports | Active MDMA doses (100 and 125 mg) produced larger CAPS reductions than a 40 mg low dose, reaching significance only in the per-protocol set (p = 0.03), with 76% no longer meeting PTSD criteria at 12-month follow-up. |
| MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? 2018 | review | Supports | Argues that MDMA-assisted psychotherapy may work by enhancing memory reconsolidation and fear extinction via modulation of emotional memory circuits, and cites durable remission in 68% of Phase 2 participants. | |
| MDMA-Assisted Psychotherapy Using Low Doses in a Small Sample of Women with Chronic Posttraumatic Stress Disorder 2008 | observational cohort | 6 | Supports | Low doses of MDMA (50-75 mg) were psychologically and physiologically safe in all six women, with preliminary efficacy data; larger samples and doses are needed. |
| Clinical applications of hallucinogens: A review. 2016 | review | Supports | A growing body of evidence indicates hallucinogens including MDMA may have therapeutic applications beyond their potential for abuse. | |
| MDMA‐Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta‐Analysis 2021 | systematic review with meta-analysis | Supports | MDMA-assisted psychotherapy reduced CAPS scores more than control psychotherapy (mean difference -22.03) with high heterogeneity, and increased rates of clinically significant improvement (RR 3.65) and loss of PTSD diagnosis (RR 2.10). | |
| Registered clinical studies investigating psychedelic drugs for psychiatric disorders. 2021 | review | 70 | Unclear | As of December 2020, 70 registered trials were investigating psychedelics for psychiatric disorders, mostly MDMA and psilocybin for PTSD and major depressive disorder, but only 21 had published results. |
| [The use of psychedelics in psychiatry]. 2026 | review | Mixed | Argues that MDMA-assisted psychotherapy has the largest phase 3 dataset in PTSD but was declined FDA approval in 2024 on ethical grounds, and that certainty of evidence remains low or very low for several indications. | |
| A Systematic Review of MDMA’s Effects on Social Cognition in Placebo-Controlled Trials 2026 | systematic review | 75 | Mixed | MDMA consistently enhanced subjective social experience but behavioural prosociality was inconsistent and context dependent, and MDMA reduced accuracy in identifying negative social cues. |
| MDMA-Assisted Therapy May Decrease PTSD Symptoms, Dissociation, Depression, and Functional Disability: A Systematic Review and Meta-Analysis 2026 | systematic review and meta-analysis | Supports | Across seven RCTs, MDMA-assisted psychotherapy may significantly improve PTSD symptoms, dissociation, depression, and functional impairment but not sleep quality, with limitations including small samples, blinding challenges, non-standardized therapies, and a common sponsor. | |
| Healing together: Results from a pilot trial of 3,4-Methylenedioxymethamphetamine-enhanced cognitive-behavioral conjoint therapy for posttraumatic stress disorder. 2026 | pilot trial | Supports | MDMA-enhanced cognitive-behavioral conjoint therapy was feasible and acceptable and was associated with clinically meaningful reductions in PTSD symptoms and improved relationship satisfaction. | |
| 717. Clinical trials, ethical dimensions, and the pathway of MDMA-assisted therapy in PTSD 2026 | literature review | Unclear | Argues that MDMA-assisted therapy trials raise distinctive ethical issues due to MDMA's affective and cognitive effects, which may heighten patient vulnerability, alter memory and beliefs, and complicate informed consent. | |
| MDMA-Enhanced Exposure Therapy Reverses PTSD-Like Features In a Learned Helplessness Mouse Model 2026 | preclinical study | Supports | MDMA combined with exposure to a traumatic cue produced rapid and sustained recovery in trauma-susceptible mice, with dose-dependent effects on anxiety- and depression-related measures. | |
| The occurrence and potential role of mystical experiences in MDMA-assisted therapy for PTSD: A secondary analysis 2026 | secondary analysis of two phase 2 RCTs | 53 | Mixed | MDMA sessions produced significantly higher MEQ30 mystical experience scores than placebo, and the Positive Mood subscale significantly mediated PTSD symptom reduction, while total and other subscale effects were non-significant. |
| Prevalence of Potential Contraindications and Risk Factors Relevant to MDMA-Assisted Therapy Among U.S. Veterans with Posttraumatic Stress Disorder 2026 | serial cross-sectional study | 326315 | Unclear | Each year 15.3-17.3% of veterans with PTSD had at least one contraindication for MDMA-assisted therapy, 55.2-58.2% had a conditional or modifiable risk factor, and 85.7-87.5% filled a prescription for a potentially interacting medication. |
| MDMA as an early post-trauma intervention in a translational animal model of PTSD. 2026 | controlled animal study | 175 | Supports | MDMA at 10 mg/kg given 30 minutes after stress or 24 hours later with trauma-cue pairing reduced anxiety-like behavior, startle, and freezing, whereas lower doses and unpaired delayed administration were ineffective. |
| Changes in trauma symptoms of discrimination after MDMA-assisted psychotherapy for posttraumatic stress disorder. 2026 | preliminary study | 5 | Supports | MDMA-assisted therapy significantly reduced discrimination-related trauma symptoms, with a 38% decrease in TSDS scores and a large effect size (d = 1.28), though the sample was very small. |
This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is MDMA for PTSD, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.
A study qualifies only when MDMA for PTSD or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.
The full method, including what a person does and does not review, is on the methods page.
194 articles · 64 from the last two years · 8,497 participants across 73 studies reporting sample size
190 studies whose primary subject is MDMA for PTSD since 2002
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 0 |
| 2004 | 0 |
| 2005 | 0 |
| 2006 | 0 |
| 2007 | 0 |
| 2008 | 1 |
| 2009 | 0 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 0 |
| 2015 | 0 |
| 2016 | 5 |
| 2017 | 1 |
| 2018 | 6 |
| 2019 | 6 |
| 2020 | 9 |
| 2021 | 21 |
| 2022 | 25 |
| 2023 | 24 |
| 2024 | 32 |
| 2025 | 29 |
| 2026 | 25 |
Orvosi hetilap September 13, 2026 Szabolcs Kéri
Over the past five years, the literature on the psychiatric use of psychedelic and related treatments has expanded substantially. Several randomized controlled trials and pooled analyses have been conducted in mood disorders, treatment-resistant depression, and post-traumatic stress disorder. Trial methodology, however, remains a fundamental source of uncertainty, and despite the popularity of...
PsyArXiv Preprints September 11, 2026 preprint
Background 3,4-Methylenedioxymethamphetamine (MDMA) is associated with distinctive prosocial and empathogenic effects, yet the consistency and scope of its impact on social cognition in humans remain unclear. Although numerous placebo-controlled studies have examined MDMA’s acute social effects, findings vary widely across subjective and behavioural domains. Methods We conducted a systematic...
Harvard Review of Psychiatry September 8, 2026 Warwick M. Green, Sanket B Raut, F. E. James et al.
There is a need for new effective treatment options for posttraumatic stress disorder (PTSD), as many people with PTSD do not fully recover despite current treatments. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AT) is emerging as a new treatment option. We assessed the current body of MDMA-AT evidence for effectiveness in treating PTSD, associated impairments, and...
J Trauma Stress September 4, 2026
Healing together: Results from a pilot trial of 3,4-Methylenedioxymethamphetamine-enhanced cognitive-behavioral conjoint therapy for posttraumatic stress disorder.
The International Journal of Neuropsychopharmacology September 1, 2026 Christopher Poppe, Dimitris Repantis
Abstract Background MDMA-assisted therapy (MDMA-AT) has shown promise for treatment-resistant post-traumatic stress disorder (PTSD), leveraging unique affective effects such as enhanced trust, empathy, and social connectedness. Despite preliminary efficacy, ethical challenges in clinical trials may directly affect regulatory approval and future clinical implementation. Aims & Objectives The...
bioRxiv (Cold Spring Harbor Laboratory) August 12, 2026 Orr Shahar, Perettz Golding, Masha Chaykin et al. preprint
Abstract Post-traumatic stress disorder (PTSD) is a highly prevalent, debilitating psychiatric condition. Existing treatments are ineffective for many patients. 3,4- methylenedioxymethamphetamine (MDMA)-assisted psychotherapy has demonstrated substantial clinical efficacy but relies on prolonged, resource-intensive therapeutic protocols that limit scalability and accessibility. Here, we...
Journal of Psychopharmacology August 6, 2026 Tijmen Bostoen, Erwin Krediet, Annette van Schagen et al.
Background: The potential safety and efficacy of the psychedelic 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) has been researched in phase 2 and phase 3 clinical trials. We examined the occurrence and role of mystical experiences in MDMA-AT. Methods: Data were sourced from two phase 2 randomized trials of MDMA-AT for chronic PTSD, in...
Journal of Psychoactive Drugs August 5, 2026 Catherine S. Hwang, David C. Cameron, Allison O’Neill et al.
3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy has emerged as a potential strategy to treat posttraumatic stress disorder (PTSD). We conducted a national serial cross-sectional study of U.S. Veterans with PTSD from January 1, 2018, to December 31, 2023, to quantify the prevalence of potential contraindications, risk factors, and drug-drug interactions relevant to MDMA-assisted...
Progress in neuro-psychopharmacology & biological psychiatry July 24, 2026 Omer Baruch, Nadav Reiss, Doron Todder et al.
Post-traumatic stress disorder (PTSD) remains difficult to prevent after trauma, highlighting the need for early interventions that reduce the risk of chronic symptom development. This controlled study investigated the preventive potential of 3,4-methylenedioxymethamphetamine (MDMA) in a validated rat model of PTSD induced by predator scent stress (PSS). Adult male Sprague-Dawley rats (N = 175)...
Scientific Reports July 11, 2026 Monnica T. Williams, Sonya C. Faber, Jordan Sloshower et al.
This preliminary study explored the effects of MDMA-assisted therapy on trauma symptoms related to discrimination, as measured by the Trauma Symptoms of Discrimination Scale (TSDS). A total of five diverse participants, who experienced multiple types of discrimination (e.g., gender, racial/ethnic, social class, age, sexual orientation), were assessed before and after treatment. A paired-samples...
Not yet recruiting Phase 2 15 participants Jenna M. Traynor
Not yet recruiting Phase 2 86 participants U.S. Army Medical Research and Development Command
Not yet recruiting Phase 2 30 participants Nautilus Sanctuary
Recruiting Phase 2 200 participants Emory University
Recruiting Phase 2 52 participants Sunstone Medical